A judge to weigh in on SNAP benefits. And, Trump wants to resume nuclear testing

A looming government shutdown threatens to cut SNAP benefits for 42 million Americans, with a federal judge now reviewing the Agriculture Department's claim of insufficient funds ($5.5 billion available versus $9 billion needed for November) and potential delays or reductions in payments. This situation, alongside projected doubling of federal insurance exchange premiums, is influencing ongoing congressional negotiations to reopen the government. Separately, President Trump's announcement to resume nuclear weapons testing, ending a decades-long moratorium, signals a significant geopolitical escalation that could disrupt global power dynamics and potentially erode the U.S.'s technological advantage if other nuclear powers follow suit.

Analysis

The impending government shutdown poses significant fiscal and social risks, with SNAP benefits for approximately 42 million Americans facing cessation due to a claimed $3.5 billion shortfall for November ($5.5 billion available vs. $9 billion needed). A federal judge is now reviewing the Agriculture Department's stance, while Democratic governors and attorneys general are challenging the legality of cutting these entitlement benefits. This fiscal impasse is further exacerbated by projected double-digit increases in federal insurance exchange premiums, intensifying political gridlock. Airlines have also urged Congress to pass a stopgap funding plan amidst air traffic controllers working without pay.

Separately, President Trump's announcement to resume nuclear weapons testing marks a significant geopolitical shift, ending a decades-long moratorium. This move is viewed by experts as a major escalation that could disrupt the global nuclear balance of power. It risks prompting other nuclear powers, such as Russia and China, to resume testing, potentially eroding the U.S.'s current technological advantage in nuclear weaponry.

In the healthcare sector, the experimental Alzheimer's drug ALZ-801 (valiltramiprosate) shows mixed but potentially promising results. While initial studies indicated no overall improvement, a subgroup analysis of 125 participants with mild cognitive impairment demonstrated a 52% slowing of cognitive decline. Despite the small sample size, the drug's oral administration and lack of brain swelling/bleeding side effects offer potential advantages over existing treatments, warranting special FDA consideration.

Key Decisions for Investors

• Monitor the progress of government shutdown negotiations and judicial rulings on SNAP benefits for potential impacts on consumer spending and specific sectors like retail and healthcare, particularly given the projected delays and reductions in aid.
• Evaluate defense sector investments for increased volatility or opportunities given the announced resumption of nuclear weapons testing and its geopolitical implications for global stability and arms races.
• Assess biotech companies with Alzheimer's drug pipelines, focusing on those with robust clinical trial designs and clear competitive advantages in efficacy or safety profiles, especially considering the challenges of small subgroup data for drugs like ALZ-801.